title: The burden of inhibitors in haemophilia patients.
abstract: The burden of disease in haemophilia patients has wide ranging implications for the family and to society. There is evidence that having a current inhibitor increases the risk of morbidity and mortality. Morbidity is increased by the inability to treat adequately and its consequent disabilities, which then equates to a poor quality of life compared with non-inhibitor patients. The societal cost of care, or `burden of inhibitors', increases with the ongoing presence of an inhibitor. Therefore, it is clear that successful eradication of inhibitors by immune tolerance induction (ITI) is the single most important milestone one can achieve in an inhibitor patient. The type of factor VIII (FVIII) product used in ITI regimens varies worldwide. Despite ongoing debate, there is in vitro and retrospective clinical evidence to support the use of plasma-derived VWF-containing FVIII concentrates in ITI regimens in order to achieve early and high inhibitor eradication success rates.
authors.forename: Christopher E
authors.initials: CE
authors.lastname: Walsh
authors.affiliation: Victor Jiménez-Yuste, Hospital Universitario La Paz - Hematology, Paseo de la Castellana 261 Apostol Santiago 61 1 J, Madrid 28017, Spain, Tel.: +34 619452698, Fax: +34 917277226, E-mail: vjyuste@gmail.com.
authors.forename: Víctor
authors.initials: V
authors.lastname: Jiménez-Yuste
authors.forename: Guenter
authors.initials: G
authors.lastname: Auerswald
authors.forename: Salvador
authors.initials: S
authors.lastname: Grancha
mesh_terms: D000818:Animals; D005169:Factor VIII / Q000276:immunology; D017048:Health Care Costs; D006467:Hemophilia A / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality*; D006801:Humans; D007108:Immune Tolerance; D011788:Quality of Life; D014841:von Willebrand Factor / Q000276:immunology
chemical_list: D014841:von Willebrand Factor; D005169:Factor VIII
keywords: FVIII; Haemophilia; immune tolerance induction; inhibitor; von Willebrand factor